Markets:

Overview

News

Currencies

International

Treasuries

AdvisorShares Dorsey Wright Short ETF (NQ:DWSH)

6.140 +0.070 (+1.15%)

Streaming Delayed Price Updated: 9:40 AM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AdvisorShares Dorsey Wright Short ETF

This Stock Is Among The Laggards In Social Media Companies — Here’s What Wall Street Expects From Its Q4 Earnings Tomorrow ↗

February 03, 2026

Snap shares have fallen nearly 45% over the past 12 months, only better than DJT, Sprout Social and Bumble over the same period.

Via Stocktwits

Snap Shares Are Tumbling Today As Focus Turns To Q4 Earnings – What Are Investors Expecting? ↗

February 02, 2026

Via Stocktwits

WHR Slips 7% — Why Is Retail Expecting Whirlpool To Eliminate Dividend? ↗

January 29, 2026

Whirlpool reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.

Via Stocktwits

Topics Earnings

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗

January 12, 2026

Via Stocktwits

Why Did Coty Offload Wella From Its Portfolio? ↗

December 19, 2025

Coty has sold its remaining 25.8% stake in Wella to KKR-managed capital accounts and investment affiliates for an upfront cash payment of $775 million.

Via Stocktwits

Topics Economy Initial Public Offering

Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug ↗

November 04, 2025

Via Stocktwits

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance ↗

October 02, 2025

Via Stocktwits

VF Corp To Sell Dickies Brand To Bluestar Alliance For $600M ↗

September 15, 2025

Via Stocktwits

Why Is SRPT Stock Falling Today? ↗

December 11, 2025

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million.

Via Stocktwits

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗

November 25, 2025

The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said.

Via Stocktwits

Thermo Fisher To Acquire Clario Holdings In A $9.4B Deal ↗

October 29, 2025

Thermo Fisher expects the acquisition to be immediately accretive to its adjusted operating margin.

Via Stocktwits

Illumina Stock Surged 6% Today – Here’s Why ↗

October 01, 2025

The company announced that its new business will focus on developing data assets, software, and artificial intelligence to drive drug development.

Via Stocktwits

Topics Artificial Intelligence

Campbell’s Gains Wall Street Confidence With Multiple Price Target Hikes, Retail Chatter Surges ↗

September 04, 2025

Via Stocktwits

This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity ↗

August 07, 2025

Via Stocktwits

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier ↗

July 18, 2025

Via Stocktwits

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why ↗

August 21, 2025

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Via Stocktwits

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗

August 11, 2025

Truist, however, kept a ‘Buy’ rating on the shares.

Via Stocktwits

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys ↗

July 29, 2025

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Via Stocktwits

Topics Death

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps ↗

July 02, 2025

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory...

Via Stocktwits

Topics Death

5 Low-Risk ETFs To Buy Amid Historic Bond Turmoil ↗

October 20, 2023

Investors are increasingly exploring diversified strategies that help to protect their portfolios from downside risk.

Via Talk Markets

Topics ETFs

Wall Street Tumbles On Renewed Fears: 5 ETFs Standing Tall ↗

August 23, 2022

Though terrible trading in the stock world pushed the ETF space into deep red on the day, a few ETFs still saw strength.

Via Talk Markets

5 ETFs That Gained Double Digits in Q2 ↗

July 03, 2022

These funds have been the quarter’s star performers and could also be winners next quarter if the current trends continue.

Via Talk Markets

5 ETFs That Gained Double Digits In Q2 ↗

July 02, 2022

While most corners of the market were deep in the red, a few have performed well. Let's take a look at the ETFs that have been the quarter’s star performers, as they could also be winners next quarter...

Via Talk Markets

Forget Recession Fears With These ETFs ↗

June 17, 2022

Here are five ETFs that could provide some shelter from the crisis and benefit investors’ portfolio.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.